» Articles » PMID: 7308275

Pharmacokinetics and Bioavailability of Tranexamic Acid

Overview
Specialty Pharmacology
Date 1981 Jan 1
PMID 7308275
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Tranexamic acid 1 g was given intravenously to three healthy volunteers. Plasma concentrations decayed in three monoexponential phases. Most elimination took place during the first eight hours, giving an apparent elimination half-life of approximately two hours. Plasma clearance ranged between 110-116 ml/min. The urinary recovery of tranexamic acid exceeded 95% of the dose. Ten healthy volunteers were given tranexamic acid 2 g orally on an empty stomach, and together with a meal. Food had no influence on the absorption of tranexamic acid, as judged by comparison of the peak plasma concentration, the time required to reach the peak, the AUC from zero to six hours, and the urinary excretion data. The oral bioavailability of tranexamic acid, calculated from 24 h urinary excretion after oral and intravenous administration, was 34% of the dose.

Citing Articles

Comparison of Tranexamic Acid Administration Methods in Rhytidectomy: A Prospective, Randomized, Double-blind Study.

Davison S, Ellor M, Hedicke C, Groth J, Grimmer K Plast Reconstr Surg Glob Open. 2025; 13(3):e6559.

PMID: 40040948 PMC: 11875600. DOI: 10.1097/GOX.0000000000006559.


Effect of Oral + Topical and Only Topical Tranaxamic Acid Application on Blood Loss and Postoperative Transfusion in Primary Total Hip Arthroplasty.

Mutlu T, Arican M, Karaduman Z, Turhan Y, Kaban I, Dalaslan R J Clin Med. 2025; 14(4).

PMID: 40004805 PMC: 11856408. DOI: 10.3390/jcm14041275.


Tranexamic acid: single topical application for femoral neck fractures treated with arthroplasty results in lowest blood loss.

Anna K, Rottinger T, Lisitano L, Koenemann N, Forch S, Mayr E Eur J Trauma Emerg Surg. 2025; 51(1):31.

PMID: 39838163 PMC: 11750898. DOI: 10.1007/s00068-024-02675-9.


Improving Adherence to National Institute for Health and Care Excellence (NICE) Guidelines for the Use of Tranexamic Acid in Primary Total Knee Arthroplasty: A Quality Improvement Initiative.

Hamed A, Hamid M, Lawrence C, Sherif I, Younis Z Cureus. 2025; 16(12):e76111.

PMID: 39835043 PMC: 11744335. DOI: 10.7759/cureus.76111.


Population pharmacokinetic model of tranexamic acid in patients who undergo cardiac surgery with cardiopulmonary bypass.

Nakai T, Tamura T, Miyagawa Y, Inagaki T, Mutsuga M, Yamada S Eur J Clin Pharmacol. 2025; 81(3):441-449.

PMID: 39820511 PMC: 11825552. DOI: 10.1007/s00228-025-03802-0.


References
1.
Eriksson O, KJELLMAN H, Pilbrant A, Schannong M . Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur J Clin Pharmacol. 1974; 7(5):375-80. DOI: 10.1007/BF00558210. View

2.
Tovi D, Nilsson I, THULIN C . Fibrinolysis and subarachnoid haemorrhage. Inhibitory effect of tranexamic acid. A clinical study. Acta Neurol Scand. 1972; 48(4):393-402. DOI: 10.1111/j.1600-0404.1972.tb07561.x. View

3.
Niazi S . Errors involved in instantaneous intravascular input assumptions. J Pharm Sci. 1976; 65(5):750-2. DOI: 10.1002/jps.2600650534. View

4.
Hedlund P . Antifibrinolytic therapy with Cyklokapron in connection with prostatectomy. A double blind study. Scand J Urol Nephrol. 1969; 3(3):177-82. DOI: 10.3109/00365596909135401. View

5.
Vessman J, Stromberg S . Determination of tranexamic acid in biological material by electron capture gas chromatography after direct derivatization in an aqueous medium. Anal Chem. 1977; 49(3):369-73. DOI: 10.1021/ac50011a012. View